Black Diamond Therapeutics (BDTX) Cash & Current Investments: 2018-2021
Historic Cash & Current Investments for Black Diamond Therapeutics (BDTX) over the last 3 years, with Sep 2021 value amounting to $235.0 million.
- Black Diamond Therapeutics' Cash & Current Investments fell 29.44% to $235.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.1 billion, marking a year-over-year increase of 5.16%. This contributed to the annual value of $315.1 million for FY2020, which is 103.71% up from last year.
- According to the latest figures from Q3 2021, Black Diamond Therapeutics' Cash & Current Investments is $235.0 million, which was down 10.80% from $263.5 million recorded in Q2 2021.
- Black Diamond Therapeutics' 5-year Cash & Current Investments high stood at $357.2 million for Q1 2020, and its period low was $39.6 million during Q2 2019.
- Moreover, its 3-year median value for Cash & Current Investments was $235.0 million (2021), whereas its average is $210.5 million.
- Per our database at Business Quant, Black Diamond Therapeutics' Cash & Current Investments soared by 698.78% in 2020 and then declined by 29.44% in 2021.
- Black Diamond Therapeutics' Cash & Current Investments (Quarterly) stood at $51.7 million in 2018, then skyrocketed by 199.39% to $154.7 million in 2019, then soared by 103.71% to $315.1 million in 2020, then decreased by 29.44% to $235.0 million in 2021.
- Its Cash & Current Investments was $235.0 million in Q3 2021, compared to $263.5 million in Q2 2021 and $290.1 million in Q1 2021.